Synapse - S. Karger AG

S. Karger AG

SHERPA: Unknown

People

Sklar
Hay
Horwitz
Offit
Vickers
Halpern
Dusza
Hamilton
Li
Marghoob

Groups

Population Sciences Research Program (35)
Survivorship Research (20)
Department of Medicine (14)
Epidemiology and Biostatistics (13)
Pediatrics, Department of (10)
General Oncology Service (9)
Health Outcomes Research Group (7)
Behavioral Sciences Service (6)
Center for Hematologic Malignancies (6)
GSK Faculty (6)

Search Within

Results (35)

Export to EndNote / Excel

Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy

Meeting Abstract

Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
Oncology Research and Treatment (2023)

Fulltext@MSK | Save

Patient-reported receipt of oncology clinician-delivered brief tobacco treatment (5As) six months following cancer diagnosis

Journal Article

Price, S. N.; Neil, J. M.; Flores, M.; Ponzani, C.; Muzikansky, A.; Ballini, L.; Ostroff, J. S.; Park, E. R.
Oncology (2023)

Fulltext@MSK | Save

Advances in the etiology, detection, and clinical management of seborrheic keratoses

Review

Sun, M. D.; Halpern, A. C.
Dermatology (2022)

Fulltext@MSK | Save

ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma

Meeting Abstract

Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Exome-wide pan-cancer analysis of germline variants in 8,719 individuals finds little evidence of rare variant associations

Journal Article

Guan, Z.; Shen, R.; Begg, C. B.
Human Heredity (2021)

Fulltext@MSK | Save

Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A+CHP) for patients (pts) with CD30+ peripheral T-cell lymphoma (ECHELON-2)

Meeting Abstract

Trümper, L.; Pro, B.; Horwitz, S.; O'connor, O.; Tilly, H.; Choi, I.; Gritti, G.; Fox, C.; Alpdogan, O.; Mayer, J.; more...
Oncology Research and Treatment (2020)

Fulltext@MSK | Save

Illustrating cancer risk: Patient risk communication preferences and interest regarding a novel BRCA1/2 genetic risk modifier test

Journal Article

Hamilton, J. G.; Genoff Garzon, M.; Shah, I. H.; Cadet, K.; Shuk, E.; Westerman, J. S.; Hay, J. L.; Offit, K.; Robson, M. E.
Public Health Genomics (2020)

Fulltext@MSK | Save

Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE registry

Journal Article

Lansigan, F.; Horwitz, S. M.; Pinter-Brown, L. C.; Rosen, S. T.; Pro, B.; Hsi, E. D.; Federico, M.; Gisselbrecht, C.; Schwartz, M.; Bellm, L. A.; more...
Acta Haematologica (2020)

Fulltext@MSK | Save

The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30(+) peripheral T-cell lymphomas (PTCLs)